# NCT02950766 (NCT02950766)

> NeoVax Plus Ipilimumab in Renal Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02950766
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Patrick Ott, MD, PhD
- Conditions: Kidney Cancer
- Interventions: NeoVax; Ipilimumab
- Enrollment: 19
- Primary outcome: Number of participants with dose-limiting toxicity (DLT) experienced within 49 days (7 weeks) of treatment initiation as assessed by CTCAE v4.0

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02950766